USD0.000æéå€ååŒÂ  (ET)
11.46MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
2.780å§å€
2.842é«å€
65.40Kåºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
--äºæ³PER
--çŽè¿12ã¶æé
åœ
1.51%売買å転ç
2.800忥çµå€
2.580å®å€
120.72K売買代é
æå€±é¡æ ªäŸ¡åçç
2.01PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-101.88%ç·è³ç£å©çç
1.14052é±é«å€
1.12åºæ¥é«æ¯ç%
-6.06MçŽå©ç
4.34Mæ ªåŒæ°
-1.62481æ ªåœããå©çïŒEPSïŒ
1.26ããŒã¿å€
-109.58%èªå·±è³æ¬å©çç
0.10052é±å®å€
9.36%æ¯ãå¹
-3381.20%ç²å©çç
11.46MæäŸ¡ç·é¡
-1.54ãªã¹ã¯ãªã¿ãŒã³
6.83%ãªã¹ã¯ç
Virax Biolabs Group Ltd ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Virax Biolabs Group Ltd
VRAX
1
Ionis Pharmaceuticals Inc
IONS
25
ææšî
ææš
売ã(2)
äžç«(2)
è²·ã(0)
ç§»åå¹³å
売ã(3)
äžç«(0)
è²·ã(3)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Virax Biolabs Group Ltdã®äŒæ¥æ
å ±î
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individualâs immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
äŒæ¥ã³ãŒãVRAX
äŒæ¥åVirax Biolabs Group Ltd
æé«çµå¶è²¬ä»»è
ãCEOãFoster (James)
ãŠã§ããµã€ãhttps://www.viraxbiolabs.com
æ ªäž»çµ±èšî
ãããã質å
Virax Biolabs Group LtdïŒVRAXïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îVirax Biolabs Group LtdïŒVRAXïŒã®çŸåšã®æ ªäŸ¡ã¯2.64ã§ãã
Virax Biolabs Group Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îVirax Biolabs Group Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯VRAXã§ãã
Virax Biolabs Group Ltdã®52é±é«å€ã¯ãããã§ããïŒ
îVirax Biolabs Group Ltdã®52é±é«å€ã¯1.14ã§ãã
Virax Biolabs Group Ltdã®52é±å®å€ã¯ãããã§ããïŒ
îVirax Biolabs Group Ltdã®52é±å®å€ã¯0.10ã§ãã
Virax Biolabs Group Ltdã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îVirax Biolabs Group Ltdã®æäŸ¡ç·é¡ã¯11.46Mã§ãã
Virax Biolabs Group Ltd (VRAX) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãVirax Biolabs Group LtdïŒVRAXïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯25.00ã§ãã
Virax Biolabs Group Ltd (VRAX) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îVirax Biolabs Group LtdïŒVRAXïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-12.64ã§ãã